<DOC>
	<DOCNO>NCT00966017</DOCNO>
	<brief_summary>The purpose study develop small molecule radio-labeled probe beta-amyloid , use positron emission tomography ( PET ) early detection treatment monitor Alzheimer disease ( AD ) . The study hypothesis PET image small molecule probe , form novel fluorescent dye radioactive label , demonstrate cerebral pattern patient AD distinct age-matched person cognitively intact .</brief_summary>
	<brief_title>Glucose Metabolic , Amyloid , Tau Brain Imaging Down Syndrome Dementia</brief_title>
	<detailed_description>This naturalistic study clinical evaluation brain scan perform 72 people Down syndrome ( DS ) , 36 non-demented 36 dementia , well 36 age-matched healthy control . Participants receive comprehensive clinical neuropsychological assessment . PET MRI scan perform baseline two year follow . All participant blood drawn APOE genotyping baseline evaluation . The intellectual range participant DS restrict IQ score 45 60 ( moderate range ) reduce variability , particularly due extreme low level intellectual ability .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>Age 45 year old No significant cerebrovascular disease modify Ischemic Score &lt; 4 Adequate visual auditory acuity allow neuropsychological test Screening laboratory test ECG without significant abnormality might interfere study Additional Inclusion Criteria Controls MMSE score 24 30 ( unless &lt; 8 year educational achievement ) The following medication allow stable &gt; 1 month : antidepressant ( without anticholinergic effect ) currently depress history major depression 2 year ; estrogen replacement therapy ; thyroid replacement therapy long individual euthyroid ; antihypertensives influence cognitive function Additional Inclusion Criteria Individuals Down syndrome Family member caregiver available ; caregiver relationship 2 year longer Karyotype DX trisomy translocation DS Mosaic form Down syndrome Englishspeaking Evidence neurological physical illness could produce cognitive deterioration ; volunteer history TIAs , carotid bruits , lacunes MRI scan exclude Parkinson 's Disease History myocardial infarction within previous year unstable cardiac disease Uncontrolled hypertension ( systolic BP &gt; 170 diastolic BP &gt; 100 ) , history significant liver disease , clinically significant pulmonary disease , diabetes , cancer Major psychiatric disorder , bipolar disorder schizophrenia Medicines could influence psychometric test result Use follow drug : centrally active betablockers , narcotic , clonidine , antiParkinsonian medication , benzodiazepine , systemic corticosteroid , medication significant cholinergic anticholinergic effect , anticonvulsant , warfarin Current diagnosis history alcoholism drug dependence Evidence untreated depression untreated anxiety Use investigational drug within previous month longer , depend drug halflife Contraindication MRI scan ( e.g. , metal body , claustrophobia ) Diagnosis possible probable AD dementia ( e.g. , vascular , Lewy body , frontotemporal ) MCI Additional Exclusion Criteria Individuals Down syndrome Mosaic form Down syndrome History clinically significant neurological disorder disease Psychiatric diagnosis treatment within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>PET Scan</keyword>
</DOC>